Why the study?
Stereotactic arrhythmia radioablation is an emerging treatment for persistent ventricular tachycardia, warranting a discussion of available clinical evidence, methodological differences, and unique challenges.
Does stereotactic arrhythmia radioablation (STAR) improve outcomes in patients with persistent ventricular tachycardia?
Does stereotactic arrhythmia radioablation (STAR) improve outcomes in patients with persistent ventricular tachycardia?
This comprehensive review summarizes the emerging clinical evidence and methodological challenges of stereotactic arrhythmia radioablation (STAR) for persistent ventricular tachycardia.
STAR for persistent VT remains investigational; leaves open the need for randomized trials to define efficacy and safety.
The electrophysiology-guided noninvasive cardiac radioablation, also known as STAR (stereotactic arrhythmia radioablation) is an emerging treatment method for persistent ventricular tachycardia. Since its first application in 2012 in Stanford Cancer Institute, and a year later in University Hospital Ostrava, Czech Republic, the authors from all around the world have published case reports and case series, and several prospective trials were established. In this article, we would like to discuss the available clinical evidence, analyze the potentially clinically relevant differences in methodology, and address some of the unique challenges that come with this treatment method.
No takes yet. Share an insight, caveat, or question.
Miszczyk et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: